Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-002 in NMOSD
NCT06557174Phase 2Not yet recruiting
- Sponsor
- ImmuneCare (Suzhou) Biopharmaceuticals Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Nov 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
A Phase 2 trial of IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by ImmuneCare (Suzhou) Biopharmaceuticals Co., Ltd.. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
IMC-002
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06557174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557174.